Last reviewed · How we verify

Diclofenac oral + scopolamina oral

Hospital de Clinicas de Porto Alegre · FDA-approved active Small molecule

Diclofenac oral + scopolamina oral is a NSAID + anticholinergic combination Small molecule drug developed by Hospital de Clinicas de Porto Alegre. It is currently FDA-approved for Acute pain with associated nausea or gastrointestinal cramping, Postoperative pain management. Also known as: Diclofenac 50 mg oral tablet, scopolamin 10 mg oral tablet.

This combination uses diclofenac to reduce pain and inflammation via COX inhibition, and scopolamine to reduce gastrointestinal motility and secretions, thereby decreasing nausea and cramping associated with the NSAID.

This combination uses diclofenac to reduce pain and inflammation via COX inhibition, and scopolamine to reduce gastrointestinal motility and secretions, thereby decreasing nausea and cramping associated with the NSAID. Used for Acute pain with associated nausea or gastrointestinal cramping, Postoperative pain management.

At a glance

Generic nameDiclofenac oral + scopolamina oral
Also known asDiclofenac 50 mg oral tablet, scopolamin 10 mg oral tablet
SponsorHospital de Clinicas de Porto Alegre
Drug classNSAID + anticholinergic combination
TargetCOX-1/COX-2 (diclofenac); muscarinic acetylcholine receptors (scopolamine)
ModalitySmall molecule
Therapeutic areaPain management / Gastroenterology
PhaseFDA-approved

Mechanism of action

Diclofenac is a nonsteroidal anti-inflammatory drug that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, providing analgesic and anti-inflammatory effects. Scopolamine is an anticholinergic agent that blocks muscarinic acetylcholine receptors in the gastrointestinal tract, reducing motility, secretions, and associated nausea—effects that help mitigate NSAID-induced GI side effects.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Diclofenac oral + scopolamina oral

What is Diclofenac oral + scopolamina oral?

Diclofenac oral + scopolamina oral is a NSAID + anticholinergic combination drug developed by Hospital de Clinicas de Porto Alegre, indicated for Acute pain with associated nausea or gastrointestinal cramping, Postoperative pain management.

How does Diclofenac oral + scopolamina oral work?

This combination uses diclofenac to reduce pain and inflammation via COX inhibition, and scopolamine to reduce gastrointestinal motility and secretions, thereby decreasing nausea and cramping associated with the NSAID.

What is Diclofenac oral + scopolamina oral used for?

Diclofenac oral + scopolamina oral is indicated for Acute pain with associated nausea or gastrointestinal cramping, Postoperative pain management.

Who makes Diclofenac oral + scopolamina oral?

Diclofenac oral + scopolamina oral is developed and marketed by Hospital de Clinicas de Porto Alegre (see full Hospital de Clinicas de Porto Alegre pipeline at /company/hospital-de-clinicas-de-porto-alegre).

Is Diclofenac oral + scopolamina oral also known as anything else?

Diclofenac oral + scopolamina oral is also known as Diclofenac 50 mg oral tablet, scopolamin 10 mg oral tablet.

What drug class is Diclofenac oral + scopolamina oral in?

Diclofenac oral + scopolamina oral belongs to the NSAID + anticholinergic combination class. See all NSAID + anticholinergic combination drugs at /class/nsaid-anticholinergic-combination.

What development phase is Diclofenac oral + scopolamina oral in?

Diclofenac oral + scopolamina oral is FDA-approved (marketed).

What are the side effects of Diclofenac oral + scopolamina oral?

Common side effects of Diclofenac oral + scopolamina oral include Dry mouth, Dizziness, Gastrointestinal upset (reduced vs. diclofenac alone), Blurred vision, Tachycardia.

What does Diclofenac oral + scopolamina oral target?

Diclofenac oral + scopolamina oral targets COX-1/COX-2 (diclofenac); muscarinic acetylcholine receptors (scopolamine) and is a NSAID + anticholinergic combination.

Related